NCT05089045View on ClinicalTrials.gov

Immunogenicity and Safety Evaluation of Recombinant Novel Coronavirus Vaccine (CHO Cells) in Enhancing Immunity

NACompletedINTERVENTIONAL

Enrollment

360

Participants

Timeline

Start Date

August 31, 2021

Primary Completion Date

September 16, 2021

Study Completion Date

September 30, 2021

Conditions

Coronavirus Disease 2019

Interventions

BIOLOGICAL

Recombinant new coronavirus vaccine (CHO cell) group

Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).

Trial Locations (1)

411228

Hunan Provincial Center for Disease Control and Prevention, Changsha

All Listed Sponsors

lead

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

INDUSTRY

NCT05089045 - Immunogenicity and Safety Evaluation of Recombinant Novel Coronavirus Vaccine (CHO Cells) in Enhancing Immunity | Biotech Hunter | Biotech Hunter